Clinical trials: Abuse Liability
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Smoking
Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum
The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three electronic cigarettes versus…
- Trial name
- NCT02269514
- Testing
- Own Brand Cigarette, Electronic Cigarette #1, Electronic Cigarette #2
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- R.J. Reynolds Vapor Company
Abuse Potential
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female…
- Trial name
- NCT04570436
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Healthy Volunteers
A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users
The purpose of this study is to evaluate the abuse potential and safety of samidorphan in healthy, non-dependent, adult, recreational opioid users.
- Trial name
- NCT02218021
- Testing
- Samidorphan, Oxycodone
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Nondependent Opioid Abuse, Episodic
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to…
- Trial name
- NCT01380093
- Testing
- MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
- Trial name
- NCT01775189
- Testing
- crushed ALO-02 30 mg/3.6 mg, crushed oxycodone IR 30 mg
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heroin Dependence, Nicotine Dependence
Pioglitazone for Heroin and for Nicotine Dependence
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy.
- Trial name
- NCT01395797
- Testing
- PIO
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Narcotic Abuse, Opioid-related Disorders
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
This was a single-dose, randomized, double-blind, placebo-controlled, 3 way crossover study designed to evaluate the relative abuse potential of crushed EMBEDA® compared to morphine sulfate CR tablets and placebo in healthy male…
- Conditions
- Narcotic Abuse, Opioid-related Disorders, Analgesia, Chronic Pain
- Trial name
- NCT01595867
- Testing
- EMBEDA - morphine sulfate/ naltrexone hydrochloride, morphine sulfate CR crushed.
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users
This randomized, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of RO4917838 in recreational drug users.
- Trial name
- NCT01438749
- Testing
- RO4917838, diazepam
- Where
- United States
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Opioid Abuse
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been characterized in a controlled laboratory setting.
- Trial name
- NCT01395784
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Tobacco Use
Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes
This study is designed to evaluate the abuse liability of mentholated very low nicotine cigarettes compared to nicotine gum and usual brand cigarettes.
- Trial name
- NCT03559725
- Testing
- VLN menthol cigarettes (A), Usual Brand Menthol Cigarettes (B), Nicotine gum (C)
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- 22nd Century Group, Inc.
Pain, Abuse, Drug
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
- Trial name
- NCT03679949
- Testing
- Oxycodone, Cannabis (THC:CBD = ~ 1:0), Cannabis (THC:CBD = ~ 0:1)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Cannabis
Repeated Administration of Cannabis Varying in THC and CBD
The majority of the >3 million medical cannabis patients in the U.S. use cannabis products to manage pain but many questions remain.
- Trial name
- NCT05563948
- Testing
- Cannabis
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Cannabis, Pain
Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans
Chronic pain is a significant public health concern in the U.S., for which prescription opioids have historically been the standard treatment. This has resulted in striking rates of opioid use disorders and fatal overdoses.
- Conditions
- Cannabis, Pain, Tolerance, Hyperalgesia
- Trial name
- NCT04596644
- Testing
- Active Cannabis
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Healthy
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
This study will evaluate the abuse potential of ALKS 5461.
- Trial name
- NCT02413281
- Testing
- ALKS 5461, Buprenorphine
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Abuse Potential
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational…
- Trial name
- NCT05319756
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Healthy
Human Psychopharmacology of Salvinorin A
This study is characterizing the subject-rated and behavioral effects of salvinorin A in healthy volunteers. The investigators hypothesize the salvinorin A will have hallucinogen-like effects.
- Trial name
- NCT00996411
- Testing
- Salvinorin A
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Electronic Nicotine Delivery System Flavors
Potential Effects of Electronic Nicotine Delivery System Flavor Regulations on African American Menthol Smokers
This study aims to better understand how the availability of electronic nicotine delivery system (aka electronic cigarettes) flavors (e.g., menthol, tobacco) impacts tobacco use behaviors, toxicant exposure, and abuse liability…
- Trial name
- RVA Flavors (NCT05023096)
- Testing
- Tobacco product administration and assessment
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Cigarette Smoking
Behavioral Economic Methods for Assessing Tobacco Product Abuse Liability: Study 7
Participants will be given the opportunity to purchase ventilated, unventilated, and alternative nicotine products at different prices using an account balance based on their typical, daily nicotine product purchasing.
- Trial name
- NCT03496922
- Testing
- Experimental Tobacco Marketplace
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Virginia Polytechnic Institute and State University
Smoking
CSD170401: Study to Assess Elements of Abuse Liability for Three Electronic Tobacco Vapor Products During an 11-Day In-Clinic Confinement
This study will examine elements of abuse liability (AL) related to potential product adoption of three electronic tobacco vapor products by current smokers relative to high and low AL comparator products (usual brand cigarette…
- Trial name
- NCT03126357
- Testing
- Product A, Product B, Product C
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company